Bristol-Myers Squibb: Kidney Neoplasms trials

The registry lists 12 Kidney Neoplasms studies with Bristol-Myers Squibb as lead sponsor. 1 are open to participants now and 3 have results posted.

Phase 1 4Phase 2 1Phase 4 2No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingNCT07195682Phase 1
• A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in IndiaCompletedNCT04513522Phase 4Results posted
• Study of Nivolumab for Advanced Cancers in IndiaCompletedNCT03444766Phase 4Results posted
• A Study of MDX-1106 in Patients With Selected Refractory or Relapsed MalignanciesCompletedNCT00441337Phase 1Results posted
• Participant Reported Outcomes and Treatment Experiences in Kidney CancerCompletedNCT04472663
• A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has SpreadCompletedNCT03663946
• Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer ParticipantsCompletedNCT03568435
• Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney CancerCompletedNCT03455452
• Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in MexicoWithdrawnNCT03161613
• Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.CompletedNCT00656734Phase 1
• Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the UrotheliumCompletedNCT00101608Phase 2
• Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney CancerCompletedNCT00095108Phase 1